GeneID: 307


Names

Common Name: TGFA-ADD2 Type: Intergenic Region
Chromosome: 2 (NC_000002.12) Locus: N/A
HUGO Symbol: TGFA-ADD2 Full Name: N/A
Exons: N/A Introns: N/A

Description:
TGFA (transforming growth factor alpha) encodes a ligand for the epidermal growth factor receptor, which activates a signalling pathway for cell proliferation, differentiation and development. ADD2 (adducin 2) belongs to a family of membrane cytoskleleton-associated proteins that promote the assembly of the spectrin-actin network. Adducins are involved in signal transduction in various cellular functions upon regulation by protein kinase C-dependent and calcium/calmodulin-dependent pathways. Adducin 2 is expressed during early erythropoiesis and at sites of cell-cell contact in epithelial tissues. Genetic variance in the TGFA-ADD2 intergenic region associated with painful episodes in patients with sickle cell disease.

Synonyms: N/A

Comments:
N/A

External Links

Publications / Origin

  1. Melton CW, Haynes J, Sickle acute lung injury: role of prevention and early aggressive intervention strategies on outcome., Clin. Chest Med., 27(3), 487-502, vii, 2006
  2. Galarneau G, Coady S, Garrett ME, Jeffries N, Puggal M, Paltoo D, Soldano K, Guasch A, Ashley-Koch AE, Telen MJ, Kutlar A, Lettre G, Papanicolaou GJ, Gene-centric association study of acute chest syndrome and painful crisis in sickle cell disease patients., Blood , 122(3), 434-42, 2013
  3. Kiang KM, Leung GK, A Review on Adducin from Functional to Pathological Mechanisms: Future Direction in Cancer., Biomed Res Int, 2018(0), 3465929, 2018
Created on 2019-10-17 09:54:26, Last reviewed on (Show full history)


Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaGenes are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.